Wall Street analysts expect that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will announce $150.25 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Ionis Pharmaceuticals’ earnings, with estimates ranging from $133.80 million to $181.50 million. Ionis Pharmaceuticals posted sales of $145.40 million during the same quarter last year, which suggests a positive year-over-year growth rate of 3.3%. The firm is expected to report its next quarterly earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Ionis Pharmaceuticals will report full year sales of $798.18 million for the current fiscal year, with estimates ranging from $738.15 million to $934.00 million. For the next fiscal year, analysts expect that the business will report sales of $951.62 million, with estimates ranging from $641.54 million to $1.81 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ionis Pharmaceuticals.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.26. The business had revenue of $164.00 million for the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The company’s revenue was up 39.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.29) EPS.
Shares of NASDAQ IONS traded up $0.64 during midday trading on Friday, hitting $62.74. The stock had a trading volume of 810,264 shares, compared to its average volume of 986,185. The company has a market capitalization of $8.25 billion, a price-to-earnings ratio of 21.20 and a beta of 1.95. Ionis Pharmaceuticals has a 1-year low of $43.27 and a 1-year high of $86.58. The company has a quick ratio of 9.93, a current ratio of 10.01 and a debt-to-equity ratio of 0.45. The company has a fifty day moving average price of $62.64 and a 200 day moving average price of $67.89.
In related news, CEO Stanley T. Crooke sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $70.25, for a total transaction of $702,500.00. Following the transaction, the chief executive officer now directly owns 79,634 shares of the company’s stock, valued at approximately $5,594,288.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $71.52, for a total value of $1,573,440.00. Following the transaction, the chairman now directly owns 79,634 shares in the company, valued at $5,695,423.68. The disclosure for this sale can be found here. Insiders own 2.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Whittier Trust Co. lifted its position in Ionis Pharmaceuticals by 283.0% during the 2nd quarter. Whittier Trust Co. now owns 383 shares of the company’s stock worth $25,000 after acquiring an additional 283 shares in the last quarter. CWM LLC lifted its position in Ionis Pharmaceuticals by 361.4% during the 2nd quarter. CWM LLC now owns 406 shares of the company’s stock worth $26,000 after acquiring an additional 318 shares in the last quarter. Ellis Investment Partners LLC acquired a new position in Ionis Pharmaceuticals during the 2nd quarter worth approximately $32,000. Rehmann Capital Advisory Group lifted its position in Ionis Pharmaceuticals by 41.3% during the 2nd quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock worth $38,000 after acquiring an additional 173 shares in the last quarter. Finally, Advisory Services Network LLC lifted its position in Ionis Pharmaceuticals by 38.5% during the 2nd quarter. Advisory Services Network LLC now owns 907 shares of the company’s stock worth $58,000 after acquiring an additional 252 shares in the last quarter. 89.05% of the stock is currently owned by hedge funds and other institutional investors.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
See Also: Equity Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.